Letter by Niccoli et al regarding article, "intracoronary versus intravenous administration of abciximab in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of st-segment elevation myocardial infarction (CICERO) trial".